Danske Bank A/S
Change company Symbol lookup
Select an option...
DNKEY Danske Bank A/S
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
MMM 3M Co
CBOE Cboe Global Markets Inc
PFE Pfizer Inc
Go

Financials : Banks | Mid Cap Value
Based in Denmark
Company profile

Danske Bank A/S is engaged in providing payment services, trading in securities and other instruments, depositing of surplus liquidity and provision of short- and long-term financing. Its segments include Personal Banking, Business Banking, Corporates & Institutions, Wealth Management, Northern Ireland, Non-core and Other Activities. The Personal Banking segment provides personal advice that addresses its customers' individual needs. The Business Banking segment offers solutions within financing, investing, cash management and risk management. The Corporates & Institutions segment provides strategic advice, financial solutions and products. The Wealth Management segment offers a range of products and services within pension savings and wealth and asset management. The Northern Ireland segment serves personal and business customers. The Non-core segment consists of loans to customers in Ireland. The Bank's Other Activities include its treasury and support functions.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$7.60
Day's Change
0.0901 (1.20%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.60
Day's Low
7.58
Volume
(Light)

Today's volume of 1,706 shares is on pace to be much lighter than DNKEY's 10-day average volume of 15,080 shares.

1,706

Moderna begins new COVID-19 vaccine study

5:15 pm ET May 29, 2020 (MarketWatch)
Print

Moderna Inc. (MRNA) announced Friday afternoon that the latest study of its potential COVID-19 vaccine has begun. The first participants in each age range have been dosed with its vaccine candidate, known as mRNA-1273, and will receive another dose 28 days later before being followed for 12 months to determine efficacy. The company intends to enroll 600 patients in the study across two age groups, 18 to 55 and older than 55. Moderna previously released limited details about its phase 1 trial of the vaccine, saying that it produced necessary antibodies in some subjects (http://www.marketwatch.com/story/modernas-stock-soars-on-compelling-early-data-for-its-coronavirus-vaccine-candidate-2020-05-18) but neglecting to provide full datasets (http://www.marketwatch.com/story/modernas-stock-soars-then-dips-after-questions-arise-around-the-limited-data-shared-about-its-covid-19-vaccine-2020-05-20). Moderna stock shot more than 10% higher Friday, with most of those gains coming in the last hour of the session. Shares were largely quiet in after-hours trading, when the announcement was made.

-Jeremy C. Owens; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 29, 2020 17:15 ET (21:15 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.